Effects of thyroid-stimulating hormone on adhesion molecules and pro-inflammatory cytokines secretion in human umbilical vein endothelial cells

Attabak Toofani Milani , Mohammad Khadem-Ansari , Yousef Rasmi

Abstract


Atherosclerosis is a multifactorial disorder, which affects the arterial wall. It has been reported that, hypothyroidism and thyroid hormone deficiency are related to cardiovascular disorders. Also, endothelial dysfunction plays an essential role in the development of atherosclerosis. We aimed to evaluate the effects of thyroid-stimulating hormone (TSH) on pro-inflammatory tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), angiogenic vascular endothelial growth factor (VEGF) and leukocyte adhesion, intercellular adhesion molecule 1 (ICAM-1) and E-selectin in human umbilical vein endothelial cells (HUVECs). In this study, HUVEC cells were treated with 1 and 2 µM of TSH in different treatment times. The gene and protein expression of ICAM-1, VEGF, and E-selectin were performed by real-time polymerase chain reaction and western blotting, respectively. Likewise, TNF-α and IL-6 protein levels were determined by the ELISA method. VEGF, ICAM-1, and E-selectin as endothelial dysfunction markers and also, TNF-α and IL-6 as pro-inflammatory cytokines were detectable in HUVEC. Besides, the results of this study revealed that TSH treatment down-regulates TNF-α and IL-6. Evaluating the gene and protein expression data revealed the upregulation of ICAM-1, E-selectin, and VEGF in TSH treated cases in different periods of exposure. Considering the multiple actions of TSH, it could be concluded that TSH plays a controversial role in atherogenesis by anti-inflammatory effects and on the other side, angiogenesis and leukocyte adhesion induction which is related to vascular cell proliferation.


Keywords


Keywords: E-selectin; HUVEC; ICAM-1; Thyrotropin; TNF-α; VEGF.

Full Text:

PDF

References


Tian L, Zhang L, Liu J, Guo T, Gao C, Ni J. Effects of TSH on the function of human umbilical vein endothelial cells. J Clin Mol Endocrinol. 2014;52(2):215-222.

Coceani M, Iervasi G, Pingitore A, Carpeggiani C, L'Abbate A. Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol. 2009;32(7):380-385.

Mayer O Jr, Šimon J, Filipovský J, Plášková M, Pikner R. Hypothyroidism in coronary heart disease and its relation to selected risk factors.

Vasc Health Risk Manag. 2006;2(4):499-506.

Cai Y, Manio MM, Leung GP, Xu A, Tang EH, Vanhoutte PM. Thyroid hormone affects both endothelial and vascular smooth muscle cells in rat arteries. Eur J Pharmacol. 2015;747:18-28.

Antunes TT, Gagnon A, Bell A, Sorisky A. Thyroid‐stimulating hormone stimulates interleukin‐6 release from 3T3‐L1 adipocytes through a cAMP‐protein kinase a pathway. Obes Res. 2005;13(12):2066-2071.

Balzan S, Del Carratore R, Nicolini G, Beffy P, Lubrano V, Forini F, et al. Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. J Clin Endocrinol Metab. 2012;97(5):1763-1770.

Tian L, Song Y, Xing M, Zhang W, Ning G, Li X, et al. A novel role for thyroid‐stimulating hormone: up‐regulation of hepatic 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme a reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology. 2010;52(4):1401-1409.

Zhang W, Tian Lm, Han Y, Ma Hy, Wang Lc, Guo J, et al. Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription. J Cell Mol Med. 2009;13(11‐12):4636-4642.

Türemen EE, Çetinarslan B, Sahin T, Cantürk Z, Tarkun I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J. 2011;58(5):349-354.

Bilgir F, Bilgir O, Calan M, Calan O, Isikyakar T. Subclinical hypothyroidism: Comparison of adhesion molecule levels before and after levothyroxine therapy. J Int Med Res. 2014;42(3):806-814.

Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem pharmacol. 2009;78(6):539-552.

Zhang H, Park Y, Wu J, Chen Xp, Lee S, Yang J, et al. Role of TNF-α in vascular dysfunction. Clin Sci (Lond). 2009;116(3):219-230.

Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94(4):534-541.

Burke‐Gaffney A, Hellewell PG. Tumour necrosis factor‐α‐induced ICAM‐1 expression in human vascular endothelial and lung epithelial cells: modulation by tyrosine kinase inhibitors. Br J Pharmacol. 1996;119(6):1149-1158.

Rahman A, Kefer J, Bando M, Niles WD, Malik AB. E-selectin expression in human endothelial cells by TNF-α-induced oxidant generation and NF-κB activation. Am J Physiol. 1998;275(3 Pt 1):L533-L544.

Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest. 1996;98(2):490-496.

Eteraf-Oskouei T, Akbarzadeh-Atashkhosrow A, Maghsudi M, Najafi M. Effects of salbutamol on the inflammatory parameters and angiogenesis in the rat air pouch model of inflammation. Res Pharm Sci. 2017;12(5):364-372.

Tian L, Zhang L, Liu J, Guo T, Gao C, Ni J. Effects of TSH on the function of human umbilical vein endothelial cells. Clin Cardiol. 2014;52(2):215-22.

Podor TJ, Jirik FR, Loskutoff DJ, Carson DA, Lotz M. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci. 1989;557(1):374-387.

Van Haasteren GA, Van der Meer MJ, Hermus AR, Linkels E, Klootwijk W, Kaptein E, et al. Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis. Endocrinol. 1994;135(4):1336-1345.

Díez JJ, Hernanz A, Medina S, Bayón C, Iglesias P. Serum concentrations of tumour necrosis factor‐alpha (TNF‐alpha) and soluble TNF‐alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf). 2002;57(4):515-521.

Kim H, Suh JM, Hwang ES, Kim DW, Chung HK, Song JH, et al. Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling. J Immunol. 2003;171(2):616-627.

Park ES, Kim H, Suh JM, Park SJ, Kwon OY, Kim YK, et al. Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells. Mol Endocrinol. 2000;14(3):440-448.

Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol. 2003;4(12):1169-1176.

Goel R, Raju R, Maharudraiah J, Kumar GSS, Ghosh K, Kumar A, et al. A signaling network of thyroid-stimulating hormone. J Proteomics Bioinform. 2011;4(10):238-241.

Sengupta TK, Schmitt EM, Ivashkiv LB. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc Natl Acad Sci U S A. 1996;93(18):9499-9504.

Ivashkiv LB, Schmitt EM, Castro A. Inhibition of transcription factor Stat1 activity in mononuclear cell cultures and T cells by the cyclic AMP signaling pathway. J Immunol. 1996;157(4):1415-1421.

Park E, You S, Kim H, Kwon O, Ro H, Cho B, et al. Hormone-dependent regulation of intercellular adhesion molecule-1 gene expression: cloning and analysis of 5´-regulatory region of rat intercellular adhesion molecule-1 gene in FRTL-5 cells. Thyroid. 1999;9(6):601-612.

An BS, Ku BJ, Park SY, Shin JK, Lee JH, Kim YK, et al. Hormonal regulation of ICAM-1 gene expression in thyroid cells, FRTL-5. Exp Mol Med. 1997;29(1):45-51.

Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183-198.

Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998;98(20):2108-2116.

Hölting T, Tezelman S, Siperstein AE, Duh QY, Clark OH. Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC-rather than PKA-activation. Biochem Biophys Res Commun. 1993;195(3):1230-1236.

Graves PN, Davies TF. New insights into the thyroid-stimulating hormone receptor: the major antigen of Graves' disease. Endocrinol Metab Clin. 2000;29(2):267-286.

Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev. 1998;19(6):673-716.

Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, et al. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab. 2004;89(12):6139-6145.

Desideri G, Bocale R, Milardi D, Ghiadoni L, Grassi D, Necozione S, et al. Enhanced proatherogenic inflammation after recombinant human TSH administration in patients monitored for thyroid cancer remnant. Clin Endocrinol (Oxf). 2009;71(3):429-433.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.